Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 7,009 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: matched placebo Clear all
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

NCT06975722
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SAR442970, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
20
States / cities
Escondido, California • Lancaster, California • Thousand Oaks, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 19, 2026, 5:03 AM EDT
Terminated Not applicable Interventional Results available

Research Study of Greater Occipital Nerve Block As A Treatment For Prolonged Migraine Attacks

NCT00329732
View directory record Official record
Conditions
Migraine
Interventions
0.5% bupivicaine and 2% lidocaine, Saline placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of VT-1598

NCT04208321
View directory record Official record
Conditions
Coccidioidomycosis
Interventions
Placebo, VT-1598
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

NCT05517421
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Batoclimab, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Beverly Hills, California • Carlsbad, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Dose of GV101 in Healthy Subjects

NCT05068947
View directory record Official record
Conditions
Phase 1
Interventions
GV101, Placebo
Drug
Lead sponsor
Graviton Bioscience Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder

NCT00758498
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
427 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Atlanta, Georgia • Crestview, Kentucky • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 19, 2026, 5:03 AM EDT
Recruiting Phase 2 Interventional

Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

NCT06699849
View directory record Official record
Conditions
Sickle Cell Disease Vaso-occlusive Crisis
Interventions
CSL889, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
20
States / cities
Oakland, California • Orange, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of ARRY-371797 in Healthy Subjects

NCT00790049
View directory record Official record
Conditions
Healthy
Interventions
ARRY-371797, p38 inhibitor; oral, Placebo; oral
Drug
Lead sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Prazosin for Agitation in Alzheimer's Disease

NCT03710642
View directory record Official record
Conditions
Alzheimer's Disease, Disruptive Behavior
Interventions
Prazosin, Placebo oral capsule
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Sun City, Arizona • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Not applicable Interventional

Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS

NCT02358694
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Serum-Derived Bovine Immunoglobulin, Placebo
Dietary Supplement · Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 19, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

NCT00455429
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, JNJ-26113100 (50 mg) once daily, JNJ-26113100 (100 mg) once daily, JNJ-26113100 (100 mg) twice daily, JNJ-26113100 (250 mg) twice daily
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Safety and Efficacy in Subjects With Chronic Cough

NCT05392192
View directory record Official record
Conditions
Chronic Cough
Interventions
ADX-629, Placebo
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Hollywood, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of SNF472 for Calciphylaxis

NCT04195906
View directory record Official record
Conditions
Calciphylaxis, Calcific Uremic Arteriolopathy
Interventions
Experimental: SNF472, Placebo Comparator: Placebo, Experimatenl SNF472 (Open-label)
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • El Centro, California • Escondido, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

NCT03681184
View directory record Official record
Conditions
Primary Hyperoxaluria Type 1 (PH1)
Interventions
Placebo, Lumasiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
San Diego, California • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Study of BHV-4157 in Alzheimer's Disease

NCT03605667
View directory record Official record
Conditions
Alzheimer Disease
Interventions
troriluzole, Placebo oral capsule
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
44
States / cities
Phoenix, Arizona • Sun City, Arizona • Fullerton, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 19, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia

NCT02204371
View directory record Official record
Conditions
Telangiectasia, Hereditary Hemorrhagic
Interventions
Pazopanib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Los Angeles, California • Augusta, Georgia • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

AT1001 for the Treatment of Long COVID

NCT05747534
View directory record Official record
Conditions
Long COVID, Long COVID-19, Post Acute COVID-19 Syndrome, Post Acute Sequelae of COVID-19
Interventions
Larazotide Acetate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 50 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

NCT04568434
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 19, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy

NCT02310763
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
PF-06252616, Placebo
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 15 Years · Male only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Oct 19, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease

NCT02831387
View directory record Official record
Conditions
Dry Eye Disease
Interventions
P-321 Ophthalmic Solution, P-321 Ophthalmic Solution placebo
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Artesia, California • Kansas City, Missouri • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 19, 2026, 5:03 AM EDT
Recruiting Phase 2 Interventional

A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

NCT07023614
View directory record Official record
Conditions
Non-obstructive Hypertrophic Cardiomyopathy
Interventions
Ninerafaxstat 200mg MR, Placebo
Drug
Lead sponsor
Imbria Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

NCT00509067
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen

NCT00638807
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Celecoxib, Placebo
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
40 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
33
States / cities
Birmingham, Alabama • Buena Park, California • Denver, Colorado + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 19, 2026, 5:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3154207 in Healthy Participants

NCT02365571
View directory record Official record
Conditions
Healthy Participants
Interventions
LY3154207, Placebo, Itraconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 19, 2026, 5:03 AM EDT